Literature DB >> 20378362

3'-(1,2,3-Triazol-1-yl)-3'-deoxythymidine analogs as substrates for human and Ureaplasma parvum thymidine kinase for structure-activity investigations.

Jay Lin1, Vincent Roy, Liya Wang, Li You, Luigi A Agrofoglio, Dominique Deville-Bonne, Tamara R McBrayer, Steven J Coats, Raymond F Schinazi, Staffan Eriksson.   

Abstract

The pathogenic mycoplasma Ureaplasma parvum (Up) causes opportunistic infections and relies on salvage of nucleosides for DNA synthesis and Up thymidine kinase (UpTK) provides the necessary thymidine nucleotides. The anti-HIV compound 3 -azido-3'-deoxythymidine (AZT) is a good substrate for TK. Methods for a rapid and efficient synthesis of new 3'-alpha-[1,2,3]triazol-3'-deoxythymidine analogs from AZT under Huisgen conditions are described. Thirteen 3'-analogues were tested with human cytosolic thymidine kinase (hTK1) and UpTK. The new analogs showed higher efficiencies (K(m)/V(max) values) in all cases with UpTK than with hTK1. Still, hTK1 was preferentially inhibited by 9 out of 10 tested analogs. Structural models of UpTK and hTK1 were constructed and used to explain the kinetic results. Two different binding modes of the nucleosides within the active sites of both enzymes were suggested with one predominating in the bacterial enzyme and the other in hTK1. These results will aid future development of anti-mycoplasma nucleosides. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378362      PMCID: PMC7744269          DOI: 10.1016/j.bmc.2010.03.023

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  40 in total

1.  Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon.

Authors:  Yoshio Saito; Vanessa Escuret; David Durantel; Fabien Zoulim; Raymond F Schinazi; Luigi A Agrofoglio
Journal:  Bioorg Med Chem       Date:  2003-08-15       Impact factor: 3.641

2.  Thymidine kinase diversity in bacteria.

Authors:  M P B Sandrini; A R Clausen; B Munch-Petersen; J Piskur
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2006       Impact factor: 1.381

3.  Structures of thymidine kinase 1 of human and mycoplasmic origin.

Authors:  Martin Welin; Urszula Kosinska; Nils-Egil Mikkelsen; Cecilia Carnrot; Chunying Zhu; Liya Wang; Staffan Eriksson; Birgitte Munch-Petersen; Hans Eklund
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

Review 4.  Ureaplasma urealyticum.

Authors:  M M Hudson; M D Talbot
Journal:  Int J STD AIDS       Date:  1997-09       Impact factor: 1.359

5.  Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U).

Authors:  L P Elwell; R Ferone; G A Freeman; J A Fyfe; J A Hill; P H Ray; C A Richards; S C Singer; V B Knick; J L Rideout
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

6.  Synthesis and antiviral activities of 1,2,3-triazole functionalized thymidines: 1,3-dipolar cycloaddition for efficient regioselective diversity generation.

Authors:  Longhu Zhou; Adel Amer; Michael Korn; Robert Burda; Jan Balzarini; Erik De Clercq; Earl R Kern; Paul F Torrence
Journal:  Antivir Chem Chemother       Date:  2005

7.  Structure of a type II thymidine kinase with bound dTTP.

Authors:  Markus S Birringer; Michael T Claus; Gerd Folkers; Daniel P Kloer; Georg E Schulz; Leonardo Scapozza
Journal:  FEBS Lett       Date:  2005-02-28       Impact factor: 4.124

8.  Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides.

Authors:  B Munch-Petersen; L Cloos; G Tyrsted; S Eriksson
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

Review 9.  Cu(I)-catalyzed Huisgen azide-alkyne 1,3-dipolar cycloaddition reaction in nucleoside, nucleotide, and oligonucleotide chemistry.

Authors:  Franck Amblard; Jong Hyun Cho; Raymond F Schinazi
Journal:  Chem Rev       Date:  2009-09       Impact factor: 60.622

10.  Molecular characterization of thymidine kinase from Ureaplasma urealyticum: nucleoside analogues as potent inhibitors of mycoplasma growth.

Authors:  Cecilia Carnrot; Rahma Wehelie; Staffan Eriksson; Göran Bölske; Liya Wang
Journal:  Mol Microbiol       Date:  2003-11       Impact factor: 3.501

View more
  6 in total

1.  Synthesis of deuterated 1,2,3-triazoles.

Authors:  Hari K Akula; Mahesh K Lakshman
Journal:  J Org Chem       Date:  2012-09-27       Impact factor: 4.354

2.  Clicking 3'-azidothymidine into novel potent inhibitors of human immunodeficiency virus.

Authors:  Venkata Ramana Sirivolu; Sanjeev Kumar V Vernekar; Tatiana Ilina; Nataliya S Myshakina; Michael A Parniak; Zhengqiang Wang
Journal:  J Med Chem       Date:  2013-10-28       Impact factor: 7.446

3.  Hypermutation of DPYD Deregulates Pyrimidine Metabolism and Promotes Malignant Progression.

Authors:  Lauren Edwards; Rohit Gupta; Fabian Volker Filipp
Journal:  Mol Cancer Res       Date:  2015-11-25       Impact factor: 5.852

4.  Phenyl 1,2,3-triazole-thymidine ligands stabilize G-quadruplex DNA, inhibit DNA synthesis and potentially reduce tumor cell proliferation over 3'-azido deoxythymidine.

Authors:  Jerald Mahesh Kumar; Mohammed M Idris; Gunda Srinivas; Pallerla Vinay Kumar; Vuppalapaty Meghah; Mitta Kavitha; Chada Raji Reddy; Prathama S Mainkar; Biswajit Pal; Srivari Chandrasekar; Narayana Nagesh
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

5.  Design, synthesis, and in vitro and in vivo biological studies of a 3'-deoxythymidine conjugate that potentially kills cancer cells selectively.

Authors:  Qiong Wei; Dejun Zhang; Anna Yao; Liyi Mai; Zhiwei Zhang; Qibing Zhou
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

Review 6.  Chemical architecture and applications of nucleic acid derivatives containing 1,2,3-triazole functionalities synthesized via click chemistry.

Authors:  Tim Efthymiou; Wei Gong; Jean-Paul Desaulniers
Journal:  Molecules       Date:  2012-10-26       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.